ERBB2 and breast carcinoma: To investigate the impact of clinic-pathological factors on the pCR rate of neoadjuvant therapy for HER2-positive breast cancer, subgroup analyses showed that there was no statistically significant difference in the impact of multiple factors on the tpCR rate of patients (Fig. 3).